- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Champix label updated to include new safety and efficacy data
24 May 2016 • Author: Victoria White, Digital Content Producer
The European Summary of Product Characteristics (SmPC) and Package Leaflet for Pfizer’s Champix (varenicline) have been updated to include safety and efficacy data from the EAGLES trial.
Varenicline is indicated for smoking cessation in adults. As part of the update, the black triangle symbol, which indicated that additional safety monitoring for varenicline in the UK was required, has been removed.
Commenting on the news, Robert West, Professor of Health Psychology, University College London and co-author of the EAGLES study, said: “The results from EAGLES and the varenicline label update should further reassure doctors and patients about the safety and effectiveness of medicines to help smokers to stop.”
The results from the trial demonstrated that the use of varenicline or bupropion in patients with or without a history of psychiatric disorder were not associated with a significantly increased risk of serious neuropsychiatric adverse events compared with placebo. In addition, patients taking varenicline in EAGLES showed statistically superior continuous abstinence rates with varenicline at weeks 9-12 and 9-24 compared with patients treated with placebo, bupropion or nicotine (Niquitin) patch.
Dr Berkeley Phillips, UK Medical Director, Pfizer, commented: “As the largest ever smoking cessation clinical trial, EAGLES provides a significant additional body of important safety and efficacy data for varenicline and today this has been reflected in the updated European regulatory label. This further supports NICE guidance which recommends varenicline as a clinically and cost effective first line treatment option for smokers wishing to quit.”
The varenicline label update was implemented following adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency and completion of the linguistic review.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics